MECP2 and myelodysplastic syndrome: Taken together, these data demonstrate that gene expression is modulated in human neurons upon an acute reduction in MECP2 dosage independent of genotype, that a subset of dysregulated genes are partially and qualitatively rescued with ASO treatment in human MDS neurons, and that these genes are involved in neural differentiation and development.